Skip to main content
. Author manuscript; available in PMC: 2010 Jan 1.
Published in final edited form as: Recent Pat Inflamm Allergy Drug Discov. 2009;3(2):96–112. doi: 10.2174/187221309788489779

Figure 2.

Figure 2

Pooling data from clinical trials of five different therapeutic strategies targeting microbial products or endogenous mediators of the host response reveal a consistent signal, suggesting clinical benefit. IL-1ra, IL-1R antagonist; MOF, multiple organ failure. Copied with permission from [23]